Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy - PubMed (original) (raw)
Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy
Hunter B Moore et al. J Trauma Acute Care Surg. 2014 Dec.
Abstract
Background: Fibrinolysis is a physiologic process maintaining patency of the microvasculature. Maladaptive overactivation of this essential function (hyperfibrinolysis) is proposed as a pathologic mechanism of trauma-induced coagulopathy. Conversely, the shutdown of fibrinolysis has also been observed as a pathologic phenomenon. We hypothesize that there is a level of fibrinolysis between these two extremes that have a survival benefit for the severely injured patients.
Methods: Thrombelastography and clinical data were prospectively collected on trauma patients admitted to our Level I trauma center from 2010 to 2013. Patients with an Injury Severity Score (ISS) of 15 or greater were evaluated. The percentage of fibrinolysis at 30 minutes by thrombelastography was used to stratify three groups as follows: hyperfibrinolysis (≥3%), physiologic (0.081-2.9%), and shutdown (0-0.08%). The threshold for hyperfibrinolysis was based on existing literature. The remaining groups were established on a cutoff of 0.8%, determined by the highest point of specificity and sensitivity for mortality on a receiver operating characteristic curve.
Results: One hundred eighty patients were included in the study. The median age was 42 years (interquartile range [IQR], 28-55 years), 70% were male, and 21% had penetrating injuries. The median ISS was 29 (IQR, 22-36), and the median base deficit was 9 mEq/L (IQR, 6-13 mEq/L). Distribution of fibrinolysis was as follows: shutdown, 64% (115 of 180); physiologic, 18% (32 of 180); and hyperfibrinolysis, 18% (33 of 180). Mortality rates were lower for the physiologic group (3%) compared with the hyperfibrinolysis (44%) and shutdown (17%) groups (p = 0.001).
Conclusion: We have identified a U-shaped distribution of death related to the fibrinolysis system in response to major trauma, with a nadir in mortality, with level of fibrinolysis after 30 minutes between 0.81% and 2.9%. Exogenous inhibition of the fibrinolysis system in severely injured patients requires careful selection, as it may have an adverse affect on survival.
Level of evidence: Prognostic study, level III.
Figures
Figure 1
Blood product transfusions between phenotypes. The y axis represents the number of specific blood products transfused within 6 hours of injury. The figure includes only patients who received a transfusion. Overall RBC and plasma transfusion units were higher in the hyperfibrinolysis phenotype and remained statistically significant after pairwise adjustment between both the physiologic and shutdown groups. *p < 0.05 after pairwise adjustment. Cryo, croprecipitate.
Figure 2
U-shaped distribution of mortality related to fibrinolysis phenotype. The y axis represents the percentage of mortality per phenotype. There is a U-shaped distribution of mortality, with a nadir in mortality identified in the physiologic group (Ly30 between 0.9% and 2.8%). Percentage of Ly30 higher and lower than this range had statistical increases in mortality. Hyper, hyperfibrinolysis; Ly30, percentage of fibrinolysis 30 minutes after reaching maximum amplitude measured by thombelastography; Physiologic, physiologic fibrinolysis; Shutdown, fibrinolysis shutdown.
Figure 3
Distribution of mortality according to fibrinolytic phenotype. The y axis represents the percentage of total mortality per phenotype. The hyperfibrinolytic phenotype had a high frequency of mortality associated with hemorrhage. The shutdown phenotype has a high frequency of organ failureYrelated death. TBI did not reach statistical difference between phenotypes but was more common in the shutdown cohort. *p < 0.05. Hyper, hyperfibrinolysis; Shutdown, fibrinolysis shutdown; TBI, traumatic brain injury.
Figure 4
Survival curve of different phenotypes of fibrinolysis. Curve demonstrates the time from injury to survival patterns between the fibrinolysis phenotypes. The y axis represents the percentage of survival, and the x axis represents hours from injury. Survival, hours after injury.
Similar articles
- Acute Fibrinolysis Shutdown after Injury Occurs Frequently and Increases Mortality: A Multicenter Evaluation of 2,540 Severely Injured Patients.
Moore HB, Moore EE, Liras IN, Gonzalez E, Harvin JA, Holcomb JB, Sauaia A, Cotton BA. Moore HB, et al. J Am Coll Surg. 2016 Apr;222(4):347-55. doi: 10.1016/j.jamcollsurg.2016.01.006. Epub 2016 Jan 22. J Am Coll Surg. 2016. PMID: 26920989 Free PMC article. - Redefining postinjury fibrinolysis phenotypes using two viscoelastic assays.
Stettler GR, Moore EE, Moore HB, Nunns GR, Silliman CC, Banerjee A, Sauaia A. Stettler GR, et al. J Trauma Acute Care Surg. 2019 Apr;86(4):679-685. doi: 10.1097/TA.0000000000002165. J Trauma Acute Care Surg. 2019. PMID: 30562328 Free PMC article. - Harmful or Physiologic: Diagnosing Fibrinolysis Shutdown in a Trauma Cohort With Rotational Thromboelastometry.
Gomez-Builes JC, Acuna SA, Nascimento B, Madotto F, Rizoli SB. Gomez-Builes JC, et al. Anesth Analg. 2018 Oct;127(4):840-849. doi: 10.1213/ANE.0000000000003341. Anesth Analg. 2018. PMID: 29683829 Free PMC article. - Fibrinolysis in trauma: a review.
Madurska MJ, Sachse KA, Jansen JO, Rasmussen TE, Morrison JJ. Madurska MJ, et al. Eur J Trauma Emerg Surg. 2018 Feb;44(1):35-44. doi: 10.1007/s00068-017-0833-3. Epub 2017 Sep 16. Eur J Trauma Emerg Surg. 2018. PMID: 28918481 Review. - Temporal Changes in Fibrinolysis following Injury.
Moore HB, Moore EE. Moore HB, et al. Semin Thromb Hemost. 2020 Mar;46(2):189-198. doi: 10.1055/s-0039-1701016. Epub 2020 Mar 11. Semin Thromb Hemost. 2020. PMID: 32160644 Review.
Cited by
- Impact of a clinical pharmacist on ultrasound-guided venous thromboembolism screening in hospitalized COVID-19 patients: a pilot prospective study.
Gillespie L, Khan RZ, Stillson JE, Bunch CM, Shariff FS, Speybroeck J, Grisoli A, Schmidt MW, Phyu H, Jablonski J, Wells B, Fulkerson DH, Oancea L, Leiser A, Walsh M. Gillespie L, et al. J Pharm Health Care Sci. 2021 Apr 1;7(1):19. doi: 10.1186/s40780-021-00201-2. J Pharm Health Care Sci. 2021. PMID: 33795030 Free PMC article. - Plasminogen activation in the musculoskeletal acute phase response: Injury, repair, and disease.
Gibson BHY, Duvernay MT, Moore-Lotridge SN, Flick MJ, Schoenecker JG. Gibson BHY, et al. Res Pract Thromb Haemost. 2020 Jun 14;4(4):469-480. doi: 10.1002/rth2.12355. eCollection 2020 May. Res Pract Thromb Haemost. 2020. PMID: 32548548 Free PMC article. Review. - Chemical Adjustment of Fibrinolysis.
Shibeko AM, Ilin IS, Podoplelova NA, Sulimov VB, Panteleev MA. Shibeko AM, et al. Pharmaceuticals (Basel). 2024 Jan 10;17(1):92. doi: 10.3390/ph17010092. Pharmaceuticals (Basel). 2024. PMID: 38256925 Free PMC article. - Euglobulin clot lysis time reveals a high frequency of fibrinolytic activation in trauma.
Ilich A, Kumar V, Ferrara MJ, Henderson MW, Noubouossie DF, Jenkins DH, Kozar RA, Park MS, Key NS. Ilich A, et al. Thromb Res. 2021 Aug;204:22-28. doi: 10.1016/j.thromres.2021.05.017. Epub 2021 May 31. Thromb Res. 2021. PMID: 34111811 Free PMC article. - TACTIC: Trans-Agency Consortium for Trauma-Induced Coagulopathy.
Mann KG, Freeman K. Mann KG, et al. J Thromb Haemost. 2015 Jun;13 Suppl 1(0 1):S63-71. doi: 10.1111/jth.12981. J Thromb Haemost. 2015. PMID: 26149052 Free PMC article. Review.
References
Publication types
MeSH terms
Grants and funding
- UM1HL120877/HL/NHLBI NIH HHS/United States
- T32 GM008315/GM/NIGMS NIH HHS/United States
- T32-GM008315/GM/NIGMS NIH HHS/United States
- UM1 HL120877/HL/NHLBI NIH HHS/United States
- P50-GM0492221/GM/NIGMS NIH HHS/United States
- UL1 TR001082/TR/NCATS NIH HHS/United States
- P50 GM049222/GM/NIGMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials